Borgeson Blake's Form 4 filing
Recursion Pharmaceuticals, Inc. (RXRX) · filed Dec 28, 2023
- Accession no.
- 0001209191-23-059947
- Filed
- Dec 28, 2023
- Trade date
- Dec 26, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction. Open-market sales total $213.2K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Borgeson BlakeCIK 0001856094 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 26, 2023 | Class A Common Stock | SSaleDisposed | −20,054 | $10.63F2 | −$213,174.02 | 7,364,472 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $10.38 to $10.89 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
Referenced by the price of 1 transaction in Table I.